Custom Anti-B7-CD28 Family Agonistic Antibody Development Service

The CD28 and B7 protein families are critical regulators of immune responses. Agonistic monoclonal antibodies against the co-stimulatory receptors of the B7-CD28 family have emerged as promising strategies to boost immune responses against cancer. Creative Biolabs, equipped with state-of-the-art antibody development technologies, is specialized in the development of novel agonistic antibody. Here, we introduce our custom-specific agonistic antibody development service targeting co-stimulatory receptors of the CD28 family.

Co-stimulatory B7-CD28 Family Receptors

The CD28 family receptors are a group of regulatory cell surface receptors expressed on different immune cells. Ligands of the CD28 receptor family belong to the B7 family proteins. Some of the CD28 family receptors are co-stimulatory receptors that mediate positive T cell regulatory functions, while the others are co-inhibitory receptors playing opposite roles in immunity. One of the co-stimulatory receptors is CD28, which is a glycoprotein constitutively expressed on the surface of naive T cells. It binds to B7-1 and B7-2 expressed on antigen-presenting cells (APCs). Signaling through this receptor induces T cell proliferation, up-regulates the anti-apoptotic molecule, and increases IL-2 production. The second co-stimulatory molecule that has been identified is the inducible co-stimulatory receptor (ICOS), whose ligand is ICOSL. This receptor is induced following T cell activation. Structurally, CD28 and ICOS have a single extracellular immunoglobulin variable-like (IgV) domain, coupled to an intracellular tail that mediates intracellular signaling. The third one is the transmembrane and immunoglobulin domain-containing protein 2 (TMIGD2) that has been reported to bind to HERV-HLTR-associated protein 2 (HHLA2).

Fig.1 The B7-CD28 family of co-stimulatory receptors. (Mayes, 2018)

Agonistic Antibody Development Targeting Co-stimulatory B7-CD28 Family Receptors

Agonistic antibody development against co-stimulatory receptor CD28 and ICOS have been reported both preclinically and clinically. For CD28, there is a TAB-08 (theralizumab) in clinical development. But the first clinical trial in 2006 observed severe systemic cytokine-release syndrome (CRS) due to the “superactivation” of T cells by TAB-08. For ICOS, agonistic antibodies, GSK-3359609 and JTX-2011, have moved into clinical trials, and are currently being tested both as monotherapies as well as a combination with PD1-blocking antibodies. The above evidence raised interests in developing more and more agonistic monoclonal antibodies targeting these co-stimulatory CD28 family receptors. Creative Biolabs, who has been devoted to the development of antibodies for research, diagnostic, and therapeutic applications for years, now offers customized agonistic antibody development services to global clients targeting various co-stimulatory receptors, including the CD28 family members. Our services are characterized by:

Advanced phage display, hybridoma technologies to aid in your agonistic antibody development requirements
Customized agonistic antibody engineering strategies to suit specific applications
A full set of in vitro and in vivo assays for testing the potency of the agonistic antibody candidates
Abundant experience with the successful discovery of agonist antibodies to a panel of receptors

With years of experience in antibody drug discovery, Creative Biolabs can deliver a range of contract research services that are tailored to their individual requirements in terms of science, timelines, and cost. For more detailed information, please feel free to contact us or directly send us an online inquiry.

Reference

Mayes, P. A.; et al. The promise and challenges of immune agonist antibody development in cancer. Nature reviews Drug discovery. 2018, 17(7): 509.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: